$20.34
3.10% today
Nasdaq, Oct 20, 07:48 pm CET
ISIN
US86627R1023
Symbol
SMMT

Summit Therapeutics PLC Sponsored ADR Stock price

$20.99
+2.90 16.03% 1M
-3.62 14.71% 6M
+3.15 17.62% YTD
-0.58 2.69% 1Y
+19.75 1,592.74% 3Y
+17.52 504.90% 5Y
+10.86 107.21% 10Y
+10.80 105.99% 20Y
Nasdaq, Closing price Fri, Oct 17 2025
-0.98 4.46%
ISIN
US86627R1023
Symbol
SMMT
Industry

Key metrics

Basic
Market capitalization
$15.6b
Enterprise Value
$15.3b
Net debt
positive
Cash
$297.9m
Shares outstanding
742.8m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
60.1
Financial Health
Equity Ratio
89.3%
Return on Equity
-56.9%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-284.1m
EBIT
- | $-947.5m
Net Income
- | $-795.6m
Free Cash Flow
$-207.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -34.7%
EBIT
- | -349.1%
Net Income
- | -259.5%
Free Cash Flow
-112.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-0.3
Short interest
30.8%
Employees
159
Rev per Employee
$0.0
Show more

Is Summit Therapeutics PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Summit Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

18x Buy
82%
2x Hold
9%
2x Sell
9%

Analyst Opinions

22 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

Buy
82%
Hold
9%
Sell
9%

Financial data from Summit Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 49 49
61% 61%
-
- Research and Development Expense 120 120
79% 79%
-
-169 -169
72% 72%
-
- Depreciation and Amortization 0.09 0.09
55% 55%
-
EBIT (Operating Income) EBIT -169 -169
72% 72%
-
Net Profit -178 -178
71% 71%
-

In millions USD.

Don't miss a Thing! We will send you all news about Summit Therapeutics PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Summit Therapeutics PLC Sponsored ADR Stock News

Neutral
Business Wire
about 7 hours ago
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter ended September 30, 2025. Planned BLA Submission for Ivonescimab in Q4 2025 Today, Summit announces that, based on the results of the HARMONi clinical trial, it plans to submit a Biol...
Neutral
Business Wire
one day ago
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as part of the Presi...
Neutral
Business Wire
3 days ago
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical development program of the novel, potential first-in-class investigational bispecific antibody, ivonescimab, into colorectal cancer (CRC) with the initiation of the global Phase III HARMONi-GI3 trial. Summit is starting a Phase III ...
More Summit Therapeutics PLC Sponsored ADR News

Company Profile

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Head office United Kingdom
CEO Robert Zanganeh
Employees 159
Founded 2003
Website www.smmttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today